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Summary  Transcatheter  aortic  valve  implantation  (TAVI),  introduced  10  years  ago  by  Alain
Cribier,  has  now  been  performed  in  more  than  50,000  patients  worldwide.  Our  vision  of  the  main
directions  for  the  future  are  fourfold.  Firstly,  the  ‘Heart  Team’  is  and  will  remain,  essential
for  patient  selection  and  the  performance  of  the  procedure.  Careful  training  and  controlled
diffusion  of  the  technique  to  medico-surgical  centres  are  also  keys  to  success.  Secondly,  patient
selection  must  be  reﬁned,  in  order  to  predict  the  risk  of  surgery  and  that  of  TAVI.  The  technique
is  currently  limited  to  very  high-risk  patients  or  those  with  contraindications  to  surgery.  It  will
be  extended  to  include  lower  risk  patients  once  there  are  adequate  trial  data,  the  safety  of  the
procedure  has  been  improved  and  better  knowledge  of  long-term  outcomes  from  the  procedure
has  been  obtained.  Thirdly,  the  procedure  will  be  simpliﬁed,  and  should  also  be  safer  with
an  expected  decrease  in  the  occurrence  of  strokes,  vascular  complications  and  perivalvular
regurgitation.  Fourthly,  the  devices  will  also  improve,  with  the  addition  of  the  potential  for
repositioning  and  improvement  in  durability.  The  role  of  imaging  with  the  use  of  multimodality
techniques  will  no  doubt  increase  and  ease  the  efﬁcacy  and  safety  of  the  procedure.  Overall,
the  use  of  TAVI  will  undoubtedly  increase  over  time,  enabling  a  larger  number  of  patients  with treated  in  an  effective  and  safe  way,  in  complement  to  surgicalsevere  aortic  stenosis  to  be
aortic  valve  replacement.
© 2012  Elsevier  Masson  SAS.  
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Résumé  L’implantation  valvulaire  aortique  par  cathéter  (TAVI),  qui  a  été  introduite  par  Alain
Cribier  il  y  a  dix  ans,  a  été  réalisée  chez  plus  de  50  000  patients  dans  le  monde.  Les  principales
directions  dans  le  futur  pourraient  être  les  suivantes  :  la  « Heart  Team  » est  et  restera  essentielle
pour  la  sélection  des  patients  et  la  réalisation  de  la  procédure.  L’entraînement  soigneux  et  la
diffusion  contrôlée  de  la  technique  à  des  centres  médicochirurgicaux  sont  aussi  des  clés  du
succès  ;  la  sélection  des  patients  doit  être  améliorée,  tant  en  ce  qui  concerne  la  prédiction  du
risque  chirurgical  que  celui  du  TAVI.  Actuellement,  la  technique  est  limitée  aux  patients  à  très
haut  risque  et  à  ceux  ayant  une  contre-indication  à  la  chirurgie.  Elle  sera  étendue  à  des  patients
à  plus  faible  risque  après  la  réalisation  des  essais  adéquats,  lorsque  la  sécurité  de  la  procédure
sera  améliorée  et  son  évolution  à  long  terme  mieux  connue  ;  la  procédure  va  se  simpliﬁer
et  devrait  devenir  plus  sûre,  avec  une  probable  diminution  du  risque  d’accident  vasculaire
cérébral,  de  complication  vasculaire  et  de  fuite  péri-valvulaire  ;  les  dispositifs  s’amélioreront
aussi  grâce  à  la  capacité  de  repositionnement  et  à  la  prolongation  de  leur  durabilité.  Avec
l’utilisation  de  techniques  multimodales,  le  rôle  de  l’imagerie  augmentera  certainement  la
simplicité  et  la  sécurité  de  la  procédure.  Globalement,  avec  le  temps,  l’utilisation  du  TAVI
va  croître  sans  aucun  doute,  permettant  à  un  plus  grand  nombre  de  patients  porteurs  d’un
rétrécissement  aortique  sévère  d’être  traités  de  fac¸on  efﬁcace  et  sûre,  en  complément  de  la
 valvu
.  
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ackground
ranscatheter  aortic  valve  implantation  (TAVI)  was  intro-
uced by  Alain  Cribier  10  years  ago  [1]  and  is  now  an
ccepted treatment  for  high-risk  patients  with  severe  aortic
tenosis.  Since  the  approval  of  both  the  Edwards  SAPIEN  and
he Medtronic  CoreValve  in  Europe  in  2007,  TAVI  has  been
erformed in  more  than  50,000  patients  worldwide  [2—6].
he current  results  of  the  technique  are  described  in  the
ther articles  of  this  issue.
Today,  TAVI  has  become  the  standard  of  care  for  inope-
able patients  with  aortic  stenosis  and  acceptable  life
xpectancy. TAVI  is  also  an  alternative  to  aortic  valve
eplacement in  selected  high-risk  operable  patients  [7,8].
he aim  of  this  review  is  to  forecast  what  may  happen  in  the
uture, starting  with  patient  selection  and  then  examining
echnical aspects.
atient selection
irst  of  all,  it  should  be  stressed  that  today  and  in  the  future,
he TAVI  Heart  Team  approach  is  and  will  remain,  essential
or the  management  of  patients  with  severe  aortic  steno-
is and  TAVI  should  be  restricted  to  high-risk  patients  [9].
his will  apply  at  each  step  of  the  procedure:  patient  selec-
ion, performance  of  the  procedure,  post-procedural  care
nd evaluation  of  the  results.
The  Heart  Team  is  comprised  of  clinical  cardiologists,
nterventionists,  surgeons,  anaesthetists  and  imaging  spe-
ialists,  all  with  expertise  in  the  treatment  of  valve  disease.
he participation  of  other  specialists,  such  as  geriatricians,
ill be  increasingly  sought.
It  is  essential  to  assess  both  the  risk  of  surgery  and  the
isk of  TAVI.  Firstly,  we  need  better  scores  to  assess  the  risk
f surgery.  The  current  scoring  systems,  EuroSCORE  or  Soci-
ty  of  Thoracic  Surgeons  Predicted  Risk  Of  Mortality  (STS
ROM) [10,11],  are  limited  in  their  prediction  of  outcomes  in
igh-risk patients.  New  scoring  systems  should  be  based  on  a
imited number  of  variables;  aimed  at  the  speciﬁc  evaluation
•laire  aortique.
  
f  valvular  patients;  elaborated  from  a  broad  spectrum  of
perative risk;  externally  validated  in  high-  and  low-volume
entres; and  updated  on  a regular  basis.  Besides  evaluating
ardiac and  extracardiac  factors,  it  is  mandatory  to  include
ndices of  functional  and/or  cognitive  capacity  and  frailty.
e need  better  deﬁnition  and  further  evaluation  of  this  last
arameter  [12].
Secondly, we  need  scoring  systems  that  predict  the  out-
ome of  TAVI,  both  in  the  immediate  and  the  long  term.  Even
ith reﬁned  scoring  systems  it  is  likely  that  it  will  never  be
magic numbers’.  Assessment  by  the  Heart  Team,  based  pri-
arily  on  clinical  judgment,  will  remain  critical,  but  will  be
upported by  a  certain  degree  of  quantiﬁcation  using  better
cores.
The use  of  TAVI  is  limited  to  patients  at  high  risk  or  with
ontraindication(s) to  surgery.  In  this  category,  a  number  of
ubgroups require  more-precise  evaluation:
associated coronary  artery  disease:  only  data  from  ret-
rospective  studies  involving  a  limited  number  of  patients
exist;  we  therefore  lack  the  solid  evidence  necessary  to
guide  our  strategy.  It  is  likely  that  randomized  studies  will
be  the  best  way  to  decide  when  percutaneous  coronary
intervention (PCI)  should  be  performed  and  the  timing  of
the  procedure  [13]  ;
bicuspid  valves  are  a  classic  contraindication  for  TAVI.
Here  again,  we  have  very  limited  data  to  guide  us,  but
this  feature  will  but  this  feature  will  become  increas-
ingly important  with  the  consideration  of  lower-risk
patients (i.e.  younger  patients).  It  may  be  that  a  spe-
ciﬁc  valve  design  is  needed  in  patients  with  bicuspid
valves [14]  ;
the  strategy  in  patients  with  severe  left  ventricular  dys-
function  is  also  a  matter  of  debate.  We  should  identify
those patients  unlikely  to  beneﬁt  from  TAVI  because  of
their  low  likelihood  of  a  good  outcome  and  in  those  we
are  willing  to  treat,  we  should  compare  a  strategy  of  bal-
rticle est publié en Open Access sous licence CC BY-NC-ND.loon  aortic  valvuloplasty  as  a  bridge  versus  TAVI  as  a  ﬁrst
intervention  ;
transcatheter  ‘valve  in  a  valve’  is  an  attractive  alter-
native  in  bioprosthesis  failure.  Preliminary  results  have
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pThe  future  of  TAVI  
been  reported  from  observational  studies,  but  more  data
are  needed  to  better  deﬁne:  which  valve  prostheses  are
suitable  for  valve-in-valve  implantation;  sizing  and  the
theoretical  risk  of  thrombosis  due  to  dual  prosthetic
implantation; and  durability.  It  is  possible  that  a  new  valve
design  will  be  needed  [15,16].
With improved  identiﬁcation  of  the  predictors  of  out-
come after  TAVI  and  thanks  to  the  involvement  of  other
specialists in  patient  selection,  it  is  likely  that  we  will  be
able to  better  deﬁne  which  patients  should  not  be  treated,
either by  surgery  or  by  TAVI  because  their  life  expectancy
and expected  quality  of  life  are  too  limited  [17,18].
The  most  important  issue  for  the  future  is  to  know  when
to treat  lower  risk  patients.  This  has  already  happened
in practice,  as  illustrated  in  a  German  registry,  where  as
many as  16%  of  patients  were  treated  as  a  result  of  patient
choice while  being  at  only  intermediate  risk  for  surgery
[3]. However,  before  moving  towards  lower  risk  patients
we should  accumulate  evidence  on  the  long-term  results
of the  procedure.  We  currently  have  only  anecdotal  cases
of valve  dysfunction,  but  the  available  follow-up  is  seldom
longer than  3—4  years  and  we  need  longer-term  data  to
better deﬁne  the  timing  and  the  mode  of  failure  [19,20].
Due to  the  similarity  of  the  valves  implanted  surgically  and
using the  transcatheter,  it  is  likely  that  both  are  similar
with regard  to  long-term  outcomes,  but  this  has  yet  to  be
proven. In  addition,  when  structural  dysfunction  occurs,  it
is likely  that  in  most  cases  it  will  be  possible  to  put  a  ‘valve
in a  valve’  and  then  further  delay  conventional  operation.
The best  way  to  assess  whether  to  move  towards  lower
risk patients  is  to  perform  randomized  studies,  such  as
the SURTAVI  and  Placement  of  Aortic  Transcatheter  Valves
(PARTNER) II  trials,  which  will  include  patients  with  a  STS
predicted mortality  rate  of  3—8%.
Finally,  it  is  unlikely  that  TAVI  will  be  used  in  a  large
number of  patients  with  aortic  regurgitation;  most  of  these
individuals have  dystrophic  disease  with  dilatation  of  the
ascending aorta,  which  should  be  cured  at  the  same  time  as
aortic stenosis  [21].
Sizing of the valve
In  the  future  we  should  be  able  to  solve  the  challenge  of
the proper  sizing  of  the  valve  [22].  Measurement  of  the  aor-
tic annulus  was  initially  done  by  echocardiography  alone.
Three-dimensional echo  or  computed  tomography  (CT)  pro-
vides more  accurate  measurements,  but  it  remains  to  be
established whether  a  strategy  based  on  CT  is  more  effec-
tive and  safer  than  an  echo-based  strategy  [23];  this  should
be proven  by  appropriately  designed  studies.  It  is  likely  that
in the  future,  CT  or  magnetic  resonance  imaging  (MRI)  will
be the  best  methods  because  they  can  be  reproduced  more
easily and  are  also  better  suited  to  the  assessment  of  the
aorta and  the  peripheral  vessels.  The  role  of  other  factors
such as  distribution  of  calcium  and  the  size  of  the  sinus  of
Valsalva should  also  be  assessed  [24,25].Performance of the procedure
The  current  recommendation  is  to  perform  the  procedure
only in  cardiology  and  cardiac  surgery  centres.  This  will
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robably  remain  the  case  because  if  we  lower  the  risk  of  the
atients, a  higher  degree  of  safety  will  be  even  more  impor-
ant and  the  feasibility  of  conversion  to  surgery  in  the  case  of
 complication  will  become  mandatory.  Perhaps  more  impor-
antly, only  large  centres  will  be  able  to  provide  appropriate
reoperative, perioperative  and  postoperative  care  [9].
Currently,  the  procedure  is  most  often  performed  in  a
atheterization laboratory.  This  will  probably  remain  the
ase in  the  near  future,  the  use  of  hybrid  rooms  is  desir-
ble, however  economic  constraints  could  limit  their  use.
herever the  procedure  is  performed,  imaging  will  play
n increasing  role  in  navigation  and  the  positioning  of  the
evices. Miniaturization  of  the  transoesophageal  echocar-
iographic probes  is  expected.  However,  it  is  likely  that  the
ositioning method  will  mainly  use  ﬂuoroscopy  and  CT.  This
ill help  in  choosing  the  most  appropriate  type  of  device
best suited  to  the  individual  anatomy)  and  then  evaluating
he position  of  the  prosthesis  in  relation  to  the  coronary
rteries (Fig.  1).  First  experimental  attempts  of  an  MRI-
uided procedure  have  been  performed  and  this  strategy  will
ecome an  attractive  option  when  MRI-compatible  devices
ecome available  [26].
The Heart  Team  in  a  given  institution  should  decide
n the  precise  organization  of  the  procedure.  One  poten-
ial strategy  is  that  interventionists  could  be  trained  to
erform surgical  access  or  surgeons  could  be  trained  to
erform catheterization;  then  these  ‘multifunctional’  indi-
iduals  could  perform  the  whole  procedure.  However,  we
o not  think  that  this  is  the  best  solution.  We  are  more
n favour  of  ‘cross-fertilization’  and  a  team  approach,  with
ach member  bringing  his  or  her  expertise  and  adding  to
he expertise  of  others.  We  feel  that  it  is  important  for
n anaesthesiologist  to  be  present.  It  is  likely  that  the  use
f general  anaesthesia  will  decrease  in  the  future  and  be
eplaced by  local  anaesthesia,  but  management  of  haemody-
amic changes  and  complications  should  still  be  harmonized
ith anaesthesiologists  specialized  in  cardiac  surgery.  They
hould  always  be  available,  especially  if  the  procedure  is
erformed in  lower-risk  patients.
The  individuals  and,  more  generally  speaking,  the  team
erforming the  procedure  should  be  carefully  trained.
heir training  should  cover:  disease,  technique  and  device-
rientated training.  All  of  the  modern  tools  should  be  used
i.e., simulator  training,  proctoring  and  teaching  courses).
ost of  the  current  training  is  provided  by  companies,  but  in
he future,  scientiﬁc  societies  and  associations  such  as  the
uropean Association  of  Percutaneous  Cardiovascular  Inter-
entions (EAPCI)  should  play  an  increasing  role  in  designing
tandards for  training  in  TAVI  [27].
Currently,  the  most  frequently  used  approach  is  trans-
emoral and  this  will  probably  increase  in  popularity  with
urther miniaturization  of  the  devices.  The  transapical
pproach also  has  a  future,  although  this  is  more  limited
28]. The  precise  roles  of  transaxillary  and  direct  aortic
ccess need  to  be  studied  in  greater  detail.  In  the  future,
t will  be  desirable  for  teams  performing  TAVI  to  be  able  to
ropose the  most  appropriate  approach  for  the  individual
atient. This  will  increase  the  number  of  patients  who  can
e treated  and  also  the  safety  of  the  procedure,  in  parti-
ular by  decreasing  the  incidence  of  vascular  complications.
ntroducers will  become  smaller  and  will  be  available  for
he transapical  approach.  Closing  devices  will  be  reﬁned;
184  A.  Vahanian  et  al.
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Figure 1. New systems for navigation and positioning during TAVI
ystem; (C) Dyna computed tomography; (D) three-dimensional tem
alve  prostheses  will  also  be  improved.  Today,  the  valve
rostheses available  are  becoming  increasingly  similar  to
he surgically  implanted  valve.  The  main  advantages  of  the
ew over  the  existing  prosthesis  designs  (Fig.  2)  are  their
epositionability and  retrievability  [29].  The  question  of
he durability  of  the  valve  should  also  be  addressed.  Users
ill then  select  the  type  of  device  used  according  to  the
i
e
i
igure 2. New prosthesis models.mini transoesophageal echocardiographic probe; (B) C-THV Paeion
e-based planning; (E) Magnetic resonance imaging guidance.
atient’s  characteristics.  Primary  studies  have  shown  the
easibility of  valves  derived  from  bone  marrow  cells  for
mplantation in  the  systemic  circulation  [30].  This  concept
s, of  course,  of  great  interest  for  the  future.
Overall  the  procedure  will  be  greatly  simpliﬁed,  with
ven wider  use  of  the  percutaneous  approach.  Pre-
mplantation balloon  dilatation  may  be  avoided  in  selected
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cases,  as  has  been  suggested  in  patients  with  mild  calciﬁca-
tion when  using  self-expandable  prostheses  [31].  However,
this simpliﬁcation  does  not  mean  that  all  of  the  necessary
team effort  and  equipment  (e.g.,  cardiac  support  and  imme-
diate access  to  surgery)  should  disappear.
The  combination  of  TAVI  with  other  transcatheter  inter-
ventions will  also  be  performed  in  the  future.  We  have
already discussed  the  issue  of  coronary  intervention  and
TAVI. Cerebral  protection  devices  may  help  to  prevent  cere-
brovascular events.  Finally,  the  potential  of  combining  TAVI
with  percutaneous  mitral  valve  repair  should  be  studied  in
selected patients.
It is  mandatory  to  decrease  the  rate  of  complications  if
we want  to  extend  the  use  of  TAVI  to  lower-risk  patients.
Stroke  has  recently  been  highlighted  as  an  important
issue after  TAVI,  but  more  work  is  needed  to  better  cha-
racterize the  type  and  timing  of  strokes  and  to  ﬁnd  the
potential causes  [8,32].  It  is  likely  that  in  the  future  we
will have  to  pay  more  attention  to  the  detection  of  severe
aortic debris,  which  may  lead  to  the  postponement  of  the
procedure or  to  the  use  of  alternative  approaches.  The
role of  embolic  protection  devices  also  has  to  be  estab-
lished, but  this  will  not  solve  the  whole  issue  because  a
sizable proportion  of  the  strokes  occur  quite  some  time  after
the procedure.  The  antithrombotic  regimen  currently  uses
dual antiplatelet  therapy.  Studies  are  ongoing  to  determine
whether one  agent  is  sufﬁcient,  which  is  of  crucial  impor-
tance in  the  elderly  population  and  in  patients  on  chronic
anticoagulant therapy.  Finally,  the  potential  role  of  antiar-
rhythmic treatment  is  an  important  issue,  since  the  role  of
transient atrial  ﬁbrillation  has  been  suggested  [33].
Moderate  to  severe  aortic  regurgitation  carries  a  poor
outcome [3].  Here  the  solution  is  to  improve  the  sizing  of
the prosthesis  and  perhaps  also  to  individualize  the  choice  of
the prosthesis.  The  strategy  of  post-implantation  dilatation
should also  be  reﬁned,  balancing  the  risk  of  aortic  regurgi-
tation against  that  of  aortic  rupture.
The  incidence  of  vascular  complications  should  decrease
with better  screening,  with  the  availability  of  smaller
devices and  introducers  and  the  use  of  alternative
approaches,  while  the  reﬁnement  of  the  antithrombotic
regimen will  also  play  a  role  [34,35].  Closure  devices  will
be improved  and  the  management  of  vascular  complications
will be  better  standardized.  In  particular,  the  respective
roles of  stenting  and  surgery  in  the  case  of  vascular  compli-
cation have  to  be  deﬁned.
The  need  for  pacemakers  is  of  less  clinical  consequence.
However, they  carry  a  cost  and  their  use  should  therefore  be
decreased [36].  This  complication  should  be  dealt  more  pre-
cisely in  patients  with  self-expandable  prostheses  and  tests
of possible  strategies  should  be  continued,  such  as  higher
valve implantation,  avoidance  of  balloon  valvuloplasty  and
performance of  post-dilatation.  Longer  follow-up  will  also
provide information  about  the  incidence  and  the  parti-
cularities of  other  complications  such  as  endocarditis  and
embolism.Evaluation of the results
Although  TAVI  is  a  relatively  new  technique  its  evaluation
has been  performed  in  an  appropriate  way  —  data  from185
andomized  studies  are  already  available,  which  is  a  posi-
ive sign.  Precise  deﬁnitions  are  mandatory  and  the  Valve
cademic Research  Consortium  effort  should  be  pursued
nd updated  [37].  Mechanistic  trials  are  needed  for  large
ingle-centre studies.  Registries  are  also  very  important  to
how real-life  aspects  and  provide  information  on  tempo-
al changes  in  the  use  of  surgery,  TAVI  and  medical  therapy.
owever, randomized  trials  will  be  key  to  expand  indica-
ions and  also  compare  devices  in  the  future.  Assessment  of
ost-effectiveness is  important  and  will  be  of  even  greater
mportance in  the  future.  Finally,  it  is  mandatory  that  at
he level  of  each  single  institution,  the  results  of  TAVI  are
arefully followed.
onclusions
 team  approach,  careful  training,  good  imaging  and  care-
ul evaluation  are  and  will  remain,  essential.  Today,  TAVI
s indicated  only  in  high-risk  patients.  Before  extending
ts use  to  low-risk  patients,  further  research  is  needed
n: risk  stratiﬁcation  models  for  aortic  valve  replace-
ent and  TAVI,  improvements  in  safety  and  ease  of  the
rocedure, technology  and  evaluation  in  comparison  with
urgery.
Transcatheter treatment  after  failure  of  valve  biopros-
hesis requires  careful  study.  It  is  most  likely  that  this  will
ecome increasingly  popular.  This  new  option  will  have
mportant clinical  implications,  increasing  the  number  of
alve bioprosthesis  implantations.
We  believe  that  the  use  of  TAVI  will  increase  over  time.
t is  also  likely  that  the  number  of  surgical  aortic  valve
eplacements will  decrease.  It  is  difﬁcult  to  predict  when
he ‘curves  will  cross’,  but  this  is  not  particularly  important.
hat is  important  is  that  a  larger  number  of  patients  with
evere aortic  stenosis  valve  disease  will  be  more  effectively
reated, whatever  the  approach.
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